Jul. 17 at 1:56 AM
$CALC Capital protection and managed exposure are my watchwords here. Unless a reverse split is accompanied by a catalyst that causes the market to revalue the company higher, it only solves the bid-price issue and leaves the MVLS deficiency unresolved. If they have no major catalyst before their September compliance deadline, their practical options narrow. They’ve can generate an increase in market capitalization through positive business or clinical developments, complete a strategic transaction (merger, acquisition, licensing, etc.) that materially increases their value, or obtain additional time through the Nasdaq hearing process. They haven’t done an R/S since 2023, so the likelihood they can get an extension, probably two, is high. The MVLS isn’t so easy. So I have to believe they have something in the works we’ll learn about shortly.
Again, capital protection and managed exposure.
GL
